Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

Ross, 2009, The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine, Oncologist, 14, 320, 10.1634/theoncologist.2008-0230 Vogel, 2010, Confirmation of a low HER2 positivity rate of breast carcinomas: limitations of immunohistochemistry and in situ hybridization, Diagn Pathol, 5, 50, 10.1186/1746-1596-5-50 Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Dawood, 2010, Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review, J Clin Oncol, 28, 92, 10.1200/JCO.2008.19.9844 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101 Marty, 2005, Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group, J Clin Oncol, 23, 4265, 10.1200/JCO.2005.04.173 Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 353, 1673, 10.1056/NEJMoa052122 Piccart-Gebhart, 2005, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N Engl J Med, 353, 1659, 10.1056/NEJMoa052306 Andersson, 2011, Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study, J Clin Oncol, 29, 264, 10.1200/JCO.2010.30.8213 Gianni, 2012, Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial, Lancet Oncol, 13, 25, 10.1016/S1470-2045(11)70336-9 Baselga, 2012, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial, Lancet, 379, 633, 10.1016/S0140-6736(11)61847-3 Baselga, 2012, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, N Engl J Med, 366, 109, 10.1056/NEJMoa1113216 Blackwell, 2012, Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study, J Clin Oncol, 30, 2585, 10.1200/JCO.2011.35.6725 Baselga, 2012, Adverse events with pertuzumab and trastuzumab: evolution during treatment with and without docetaxel in CLEOPATRA, Proc Am Soc Clin Oncol, 30 Lan, 1983, Discrete sequential boundaries for clinical trials, Biometrika, 70, 659, 10.2307/2336502 Swain, 2013, Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study, Oncologist, 18, 257, 10.1634/theoncologist.2012-0448 von Minckwitz G, Baselga J, Bradbury I, et al. Adjuvant pertuzumab and Herceptin in initial therapy of breast cancer: APHINITY (BIG 4-11/BO25126/TOC4939g). San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 6–10, 2011. OT1-02-04 (abstr). Verma, 2012, Trastuzumab emtansine for HER2-positive advanced breast cancer, N Engl J Med, 367, 1783, 10.1056/NEJMoa1209124 Baselga, 2012, Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer, N Engl J Med, 366, 520, 10.1056/NEJMoa1109653 Cho, 2003, Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab, Nature, 421, 756, 10.1038/nature01392 Junttila, 2009, Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941, Cancer Cell, 15, 429, 10.1016/j.ccr.2009.03.020 Scheuer, 2009, Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models, Cancer Res, 69, 9330, 10.1158/0008-5472.CAN-08-4597 Molina, 2001, Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells, Cancer Res, 61, 4744 Franklin, 2004, Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex, Cancer Cell, 5, 317, 10.1016/S1535-6108(04)00083-2 Agus, 2002, Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth, Cancer Cell, 2, 127, 10.1016/S1535-6108(02)00097-1 Nahta, 2004, The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells, Cancer Res, 64, 2343, 10.1158/0008-5472.CAN-03-3856 O'Shaughnessy, 2004, Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer, Clin Breast Cancer, 5, 142, 10.3816/CBC.2004.n.019 Livingston, 2011, SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer, Breast Cancer Res Treat, 130, 123, 10.1007/s10549-011-1698-5 Valero, 2011, J Clin Oncol, 29, 149, 10.1200/JCO.2010.28.6450